Trends in the Netherland’s breast cancer recurrence rates between 2003 and 2011

乳腺癌是全世界女性人群中最常见的恶性肿瘤。由于非常有效的治疗理念，乳腺癌患者的生存率在过去几年中一直在增加。那些在确诊后存活下来的人，尽管害怕肿瘤复发。几年前，荷兰特文特大学的科学家们发起了一个“影响项目”，并开发了一个预测模型，估计患者患肿瘤复发的个体风险。然而，这个易于操作的工具只粗略地考虑了所应用的治疗措施的细节。在过去的十年中，许多新的个体治疗概念被建立。因此，存在患者特征和治疗选项的无数可能组合。为了识别非常有利或特别不利的患者治疗组合，需要进行大数据分析。该项目的数据将由美国癌症登记中心NCR提供。自1989年以来，它收集所有荷兰恶性诊断患者的信息。因此，我们的邻国为高水平开展卫生服务研究提供了理想的条件。本研究将纳入2003年至2011年间超过63，000例浸润性乳腺癌患者，随访时间超过5年。当然，随机对照试验是分析新疗法影响的金标准。尽管如此，注册研究为在日常临床实践中实施新疗法后检查肿瘤学结局提供了真正客观的条件。因此，本研究的结果有望支持更定制的治疗和监测概念的发展。

Breast cancer is the most frequent malignant tumor within the female population worldwide. Due to very effective therapy concepts the survival rates of patients with mamma-carcinoma have been increasing during the past years. People who managed to survive their diagnosis in the first place though dread tumor recurrence ever after.Some years ago, scientists of the Dutch university of Twente initiated the "influence-project" and developed a prognostic model estimating a patient’s individual risk to suffer from tumor recurrence. However, this easy-to-handle tool considers details on applied therapy measures only rudimentarily. During the last decade, many new individual therapy concepts were established. As a consequence, there exist countless possible combinations of patient characteristics and therapy options. To identify very favorable or particularly adverse patient-therapy-combinations, big-data-analysis is required.Data for this project will be provided by the Netherland’s cancer registry NCR. Since 1989 it collects information on all Dutch patients with malignant diagnoses. Therefore, our neighbor country offers ideal conditions to conduct health services research on a high level. For the purpose of this study, over 63,000 patients with an invasive mamma-carcinoma between 2003 and 2011 and a follow-up period of more than five years will be considered.Of course, randomized controlled trials are gold-standard to analyze the impact of new therapies. Nevertheless, registry research provides truly objective conditions for examining oncologic outcomes after the implementation of new therapies in daily clinical practice. The results of this study thus hopefully will support the development of more customized therapy and surveillance concepts.